Novartis AG banner

Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 125.02 CHF 1.43% Market Closed
Market Cap: CHf239.9B

Relative Value

The Relative Value of one NOVN stock under the Base Case scenario is hidden CHF. Compared to the current market price of 125.02 CHF, Novartis AG is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

NOVN Competitors Multiples
Novartis AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Novartis AG
SIX:NOVN
238.2B CHF 5.5 22.1 13.7 17.5
US
Eli Lilly and Co
NYSE:LLY
952.7B USD 14.6 46.2 31.1 33.2
US
Johnson & Johnson
NYSE:JNJ
584.1B USD 6.2 21.8 15.1 18.6
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 20.4 12 13.6
UK
AstraZeneca PLC
LSE:AZN
223.5B GBP 5.1 29.3 16.2 22.9
US
Merck & Co Inc
NYSE:MRK
289.8B USD 4.5 15.9 9.9 12
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.9 8.1 9.5
US
Pfizer Inc
NYSE:PFE
152.4B USD 2.4 19.6 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 2.5 17.3 7.3 9
UK
GlaxoSmithKline PLC
LSE:GSK
83.2B GBP 2.5 14.5 7.4 10.5
P/E Multiple
Earnings Growth PEG
CH
Novartis AG
SIX:NOVN
Average P/E: 21.8
22.1
14%
1.6
US
Eli Lilly and Co
NYSE:LLY
46.2
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
CH
Roche Holding AG
SIX:ROG
20.4
14%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.3
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1
UK
GlaxoSmithKline PLC
LSE:GSK
14.5
14%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Novartis AG
SIX:NOVN
Average EV/EBITDA: 43
13.7
5%
2.7
US
Eli Lilly and Co
NYSE:LLY
31.1
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.6
CH
Roche Holding AG
SIX:ROG
12
6%
2
UK
AstraZeneca PLC
LSE:AZN
16.2
13%
1.2
US
Merck & Co Inc
NYSE:MRK
9.9
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.1
1%
8.1
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-10%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Novartis AG
SIX:NOVN
Average EV/EBIT: 92.9
17.5
9%
1.9
US
Eli Lilly and Co
NYSE:LLY
33.2
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
18.6
7%
2.7
CH
Roche Holding AG
SIX:ROG
13.6
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
22.9
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9
-7%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
10.5
7%
1.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett